Literature DB >> 7726491

Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin.

A van 't Veen1, J W Mouton, D Gommers, J A Kluytmans, P Dekkers, B Lachmann.   

Abstract

The influence of a natural pulmonary surfactant on antibiotic activity was investigated to assess the possible use of exogenous surfactant as a vehicle for antibiotic delivery to the lung. The influence of surfactant on the bactericidal activity of amoxicillin was tested against Staphylococcus aureus and Streptococcus pneumoniae, and the influence of surfactant on the activities of ceftazidime and tobramycin was tested against Klebsiella pneumoniae, Pseudomonas aeruginosa, S. aureus, and S. pneumoniae. In vitro antibiotic activity was determined by killing curve studies in media with and without surfactant. Amoxicillin and ceftazidime activities were not changed in the presence of surfactant, except for a decreased killing rate of S. pneumoniae by ceftazidime in medium with additional rabbit serum. In contrast, killing curves with low concentrations of tobramycin (0.25x and 1x the MIC) showed a decreased level of activity of tobramycin against all pathogens tested in the presence of surfactant. With higher tobramycin concentrations (4x the MIC) killing rates were decreased less or were unchanged in the presence of surfactant. Concluding from the results of the study, both amoxicillin and ceftazidime can be combined with surfactant without the loss of activity. For mixing surfactant with tobramycin, dosages should be adjusted to overcome the partial inactivation of tobramycin by surfactant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726491      PMCID: PMC162536          DOI: 10.1128/AAC.39.2.329

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability.

Authors:  F Bressolle; J E de la Coussaye; R Ayoub; D Fabre; R Gomeni; G Saissi; J J Eledjam; M Galtier
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

3.  Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides.

Authors:  A L Barry; L B Reller; G H Miller; J A Washington; F D Schoenknect; L R Peterson; R S Hare; C Knapp
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

Review 4.  Systemic antibiotic treatment of nosocomial pneumonia.

Authors:  K E Unertl; F P Lenhart; H Forst; K Peter
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

5.  Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs.

Authors:  V S Kharasch; T D Sweeney; J Fredberg; J Lehr; A I Damokosh; M E Avery; J D Brain
Journal:  Am Rev Respir Dis       Date:  1991-10

6.  Testing Staphylococcus aureus for resistance to beta-lactams.

Authors:  F W Goldstein; J Acar
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

7.  Lung distribution and pharmacokinetics of aerosolized tobramycin.

Authors:  P Le Conte; G Potel; P Peltier; D Horeau; J Caillon; M E Juvin; M F Kerguéris; D Bugnon; D Baron
Journal:  Am Rev Respir Dis       Date:  1993-05

8.  Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats.

Authors:  E P Eijking; G J van Daal; R Tenbrinck; A Luijendijk; J F Sluiters; E Hannappel; B Lachmann
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

9.  Exogenous surfactant therapy increases static lung compliance, and cannot be assessed by measurements of dynamic compliance alone.

Authors:  D Gommers; C Vilstrup; J A Bos; A Larsson; O Werner; E Hannappel; B Lachmann
Journal:  Crit Care Med       Date:  1993-04       Impact factor: 7.598

10.  Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice.

Authors:  G J Van Daal; J A Bos; E P Eijking; D Gommers; E Hannappel; B Lachmann
Journal:  Am Rev Respir Dis       Date:  1992-04
View more
  13 in total

1.  Effect of pulmonary surfactant on antimicrobial activity in vitro.

Authors:  R Schwameis; Z Erdogan-Yildirim; M Manafi; M A Zeitlinger; S Strommer; R Sauermann
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

2.  Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae.

Authors:  A van't Veen; J W Mouton; D Gommers; B Lachmann
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model.

Authors:  Aaron J Heffernan; Fekade B Sime; Derek S Sarovich; Michael Neely; Yarmarly Guerra-Valero; Saiyuri Naicker; Kyra Cottrell; Patrick Harris; Katherine T Andrews; David Ellwood; Steven C Wallis; Jeffrey Lipman; Keith Grimwood; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle.

Authors:  A Van't Veen; D Gommers; S J Verbrugge; P Wollmer; J W Mouton; P P Kooij; B Lachmann
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 5.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity.

Authors:  A van 't Veen; D Gommers; J W Mouton; J A Kluytmans; E J Krijt; B Lachmann
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

7.  Human Bile Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and Escherichia coli In Vitro.

Authors:  Beatrix Wulkersdorfer; David Jaros; Sabine Eberl; Stefan Poschner; Walter Jäger; Enrico Cosentini; Markus Zeitlinger; Richard Schwameis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia.

Authors:  Brandon J H Banaschewski; Edwin J A Veldhuizen; Eleonora Keating; Henk P Haagsman; Yi Y Zuo; Cory M Yamashita; Ruud A W Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

9.  Influence of a pulmonary surfactant on the in vitro activity of tobramycin against Pseudomonas aeruginosa.

Authors:  E J Caldwell; D S Piper
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

10.  Exogenous pulmonary surfactant as a vehicle for antimicrobials: assessment of surfactant-antibacterial interactions in vitro.

Authors:  Alexei Birkun
Journal:  Scientifica (Cairo)       Date:  2014-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.